NASDAQ:IBIO

iBio (IBIO) Stock Price, News & Analysis

iBio logo
$0.71 -0.03 (-3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 -0.01 (-0.81%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About iBio Stock (NASDAQ:IBIO)

Advanced

Key Stats

Today's Range
$0.68
▼
$0.77
50-Day Range
$0.71
▼
$1.33
52-Week Range
$0.68
▼
$3.82
Volume
588,980 shs
Average Volume
1.06 million shs
Market Capitalization
$49.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Buy

Company Overview

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology.

The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development.

iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery. Its programs are in development, and the company’s research priorities may change as its pipeline advances.

AI Generated. May Contain Errors.

iBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
48th Percentile Overall Score

IBIO MarketRank™: 
2.413861648555 of 5 stars

iBio scored higher than 48% of companies evaluated by MarketBeat, and ranked 564th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    iBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    iBio has a consensus price target of $6.00, representing about 749.0% upside from its current price of $0.71.

  • Amount of Analyst Coverage

    iBio has only been the subject of 2 research reports in the past 90 days.

  • Read more about iBio's stock forecast and price target.
  • Earnings Growth

    Earnings for iBio are expected to decrease in the coming year, from ($0.35) to ($0.53) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of iBio is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of iBio is -2.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    iBio has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.37% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 7.15.
  • Change versus previous month

    Short interest in iBio has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    iBio does not currently pay a dividend.

  • Dividend Growth

    iBio does not have a long track record of dividend growth.

  • News Sentiment

    iBio has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for iBio this week, compared to 2 articles on an average week.
  • Search Interest

    17 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 70% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added iBio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iBio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.55% of the stock of iBio is held by insiders.

  • Percentage Held by Institutions

    7.90% of the stock of iBio is held by institutions.

  • Read more about iBio's insider trading history.
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IBIO Stock News Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Brookline Capital Markets Boosts Earnings Estimates for iBio
iBio (IBIO) Set to Announce Quarterly Earnings on Wednesday
See More Headlines

IBIO Stock Analysis - Frequently Asked Questions

iBio's stock was trading at $1.93 on January 1st, 2026. Since then, IBIO shares have decreased by 63.4% and is now trading at $0.7067.

iBio, Inc. (NASDAQ:IBIO) released its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The business earned $1.08 million during the quarter, compared to the consensus estimate of $25 thousand.

Shares of iBio reverse split before market open on Wednesday, November 29th 2023.The 1-20 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of iBio include Marshall Wace LLP (1.09%), Noesis Capital Mangement Corp (0.39%), State Street Corp (0.34%) and Landscape Capital Management L.L.C. (0.14%). Insiders that own company stock include Felipe Duran, Martin Brenner and David Arkowitz.
View institutional ownership trends
.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Tesla (TSLA), NIO (NIO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Moderna (MRNA).

Company Calendar

Last Earnings
11/10/2026
Today
11/16/2026
38th Annual Healthcare Conference
12/01/2026
Fiscal Year End
6/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IBIO
Previous Symbol
NYSEMKT:IBIO
CIK
1420720
Employees
23
Year Founded
N/A

Price Target and Rating

High Price Target
$7.00
Low Price Target
$5.00
Potential Upside/Downside
+749.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$33.04 million
Net Margins
N/A
Pretax Margin
-3,244.19%
Return on Equity
-40.05%
Return on Assets
-35.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.48
Quick Ratio
9.48

Sales & Book Value

Annual Sales
$100 thousand
Price / Sales
497.94
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.54 per share
Price / Book
0.46

Miscellaneous

Outstanding Shares
70,460,000
Free Float
69,364,000
Market Cap
$49.79 million
Optionable
N/A
Beta
1.48
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:IBIO) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners